1. Home
  2. /
  3. Stock Market News
  4. /
  5. 3 Top Rated Stocks That Analysts Love This Week!

3 Top Rated Stocks That Analysts Love This Week!

Amrit - October 04, 2021

top rated stocks featured

These three top rated stocks have a 50% upside according to forecasts from leading analysts!

Below, we detail the company, its growth, and future projections. 

Source: wallstrank.com

(Click HERE for our review of Wall St Rank and their stock picking service!)

The top 3 stocks for the week of October 4, 2021 are: 

1) Futu Holdings

Company Profile:

http://www.futuholdings.com

Sector(s): Financial Services

Industry: Capital Markets

Full-time employees: 1,315

Futu Holdings Limited operates an online brokerage and wealth management platform in Hong Kong and internationally.

The company provides trading, clearing, and settlement services; margin financing and securities lending services; and a stock yield enhancement program.

Market Cap: $ 13.37 B
Beta: 1.23

Average Growth Rates (Past 5 Years)

  • Revenue: +741.61%
  • Net Income: -289.45%
  • Earnings Per Share: -257.47%
  • Capital Spending: +201.33%
  • Gross Margin: +74.20%
  • Cash Flow: +194.87%

3 top rated stocks

 

Historical Quarterly Performance

  • Q3 2020: Beat 
  • Q4 2021: Beat
  • Q1 2021: Beat 
  • Q2 2021: Missed

Consensus Analyst Projections

3 top rated stocks

Latest Ratings Breakdown (Current)

  • STRONG BUY: 89%
  • HOLD: 11%

 Latest Price Targets (Last 3 months)

  • Aug 2, 2021: BOCOM International upgrades the stock to a STRONG BUY rating with a price target of $142 
  • Jul 14, 2021: Goldman Sachs initiates coverage with a HOLD rating with a price target of $158

Latest Price Target Range (Last 3 months)

  • Lowest: $ 120 (+33% upside)
  • Highest $ 255 (+183 % upside)

 

Ready to build your portfolio? With Public.com you can follow other investors, discover companies that are inline with your beliefs, and invest into stocks and crypto with very little money! What are you waiting for? Check out Public Now!

Stock Advice That Beats The Market! Stock Advisor's recommendations have beaten the market over the past 19 years. Tired of picking losers? Stock Dork readers can join for only $99 a year! Check out Stock Advisor today!

2) Exact Sciences

Company Profile:

http://www.exactsciences.com
Sector(s): Healthcare

Industry: Diagnostics & Research

Crypto Alert
I’m A One Percenter

It doesn’t matter if you have $500 or $5 million. 

Here’s what I recommend you do with your money right now.

ATTENTION: The following video is a serious financial warning from one of America’s richest men. He believes this event will make the rich even richer while financially affecting countless others and fan the flames of social protest.

It’s free to watch and by doing so I believe you’ll be ahead of everyone else struggling to understand what is really going on. I hope you take advantage of this opportunity!

Click Here For All Of The Details
We earn a commission if you click this link and make a purchase at no additional cost to you.

Full-time employees: 4,800

Exact Sciences Corporation is in the healtcare sector and provides cancer screening and diagnostic test products in the United States and internationally.

The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Market Cap: $ 16.53.32 B 

Beta: 1.29

5-year Historical Growth:

  • Revenue: +280.15%
  • Net Income: +81.49%
  • Earnings Per Share: +48.72%
  • Capital Spending: +66.66%
  • Gross Margin: +76.61%
  • Cash Flow: -31.17%

 

3 top rated stocks

Historical Quarterly Performance

  • Q3 2020: Missed 
  • Q4 2021: Missed
  • Q1 2021: Beat 
  • Q2 2021: Missed

Consensus Analyst Projections

 

3 top rated stocks

 

Latest Ratings Breakdown (Current)

  • STRONG BUY: 75%
  • BUY: 10%
  • HOLD: 15%
     

Latest Price Targets (Last 3 months)

  • Jul 29, 2021: Kyle Mikson from Canaccord Genuity maintains a STRONG BUY rating  with a price target of $160 
  • Jul 29, 2021: Kevin Degeeter from Oppenheimer (top 4% analyst), maintains a BUY rating  with a price target of $155
  • Jul 14, 2021: Puneet Souda from SVB Leerink (top 7% analyst), maintains a BUY rating  with a price target of $160

Latest Price Target Range (Last 3 months)

  • Lowest: $ 120 (+25% upside)
  • Highest $ 165 (+72% upside)

 

3) Guardant Health

Company Profile:

http://guardanthealth.com
Sector(s): Healthcare

Industry: Diagnostics & Research

Full-time employees: 864

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally.

The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer; and GuardantINFORM, an in-silico research platform that is compromised of a clinical-genomic liquid biopsy dataset of advanced cancer patients. 

Market Cap: $ 10.90 B
Beta: 0.5

Average Growth Rates (Past 5 Years)

  • Revenue: +90.01%
  • Net Income: -289.45%
  • Earnings Per Share: +76.39%
  • Capital Spending: +592.22%
  • Gross Margin: +56.18%
  • Cash Flow: +49.68%

 

3 top rated stocks

Historical Quarterly Performance

  • Q3 2020: Missed
  • Q4 2021: Missed
  • Q1 2021: Missed
  • Q2 2021: Missed

Consensus Analyst Projections

3 top rated stocks


Latest Ratings Breakdown (Current)

  • STRONG BUY: 82%
  • BUY: 6%
  • HOLD: 6%
  • UNDERWEIGHT: 6%

 Latest Price Targets (Last 3 months)

  • Jun 21, 2021: Dan Leonard from Wells Fargo  (top 4% analyst), maintains a STRONG BUY rating with a price target of $160 

Latest Price Target Range (Last 3 months)

  • Lowest: $ 130 (+21% upside)
  • Highest $ 185 (+73 % upside)